Erythrophagocytes in hemolytic anemia, wound healing, and cancer.
NRF2
erythrophagocytosis
heme
hemolysis
macrophage
tumor-associated macrophage
Journal
Trends in molecular medicine
ISSN: 1471-499X
Titre abrégé: Trends Mol Med
Pays: England
ID NLM: 100966035
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
received:
02
06
2022
revised:
11
08
2022
accepted:
11
08
2022
pubmed:
13
9
2022
medline:
2
11
2022
entrez:
12
9
2022
Statut:
ppublish
Résumé
Hemolysis is a ubiquitous pathology defined as premature red blood cell destruction within the circulation or local tissues. One of the most archetypal functions of macrophages is phagocytosis of damaged or extravasated red blood cells, preventing the extracellular release of toxic hemoglobin and heme. Upon erythrophagocytosis, spiking intracellular heme concentrations drive macrophage transformation into erythrophagocytes, leveraging antioxidative and iron recycling capacities to defend against hemolytic stress. This unique phenotype transformation is coordinated by a regulatory network comprising the transcription factors BACH1, SPI-C, NRF2, and ATF1. Erythrophagocytes negatively regulate inflammation and immunity and may modulate disease-specific outcomes in hemolytic anemia, wound healing, atherosclerosis, and cancer. In this opinion article, we outline the known and presumed functions of erythrophagocytes and their implications for therapeutic innovation and research.
Identifiants
pubmed: 36096988
pii: S1471-4914(22)00210-6
doi: 10.1016/j.molmed.2022.08.005
pii:
doi:
Substances chimiques
Heme
42VZT0U6YR
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
906-915Informations de copyright
Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests The authors declare that no conflict of interest exists.